Developer docs
API playgroundTry for free, no card

Search company profiles

Herantis Pharma

Full company profile

uuid00049kz

Namestring
Herantis Pharma
Legal namestring
Herantis Pharma Oyj
Websiteurl
herantis.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Herantis Pharma is a Finnish clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with its primary focus on Parkinson's disease. The company is headquartered in Espoo, Finland (Bertel Jungin Aukio 1, FIN-02600), is listed on Nasdaq First North Growth Market Finland under ticker HRTIS, and operates as a public limited liability company (Herantis Pharma Oyj / Plc). The company's lead product candidate is HER-096, a first-in-class blood-brain barrier penetrating peptide therapy that modulates multiple disease-relevant pathways — proteostasis, mitochondrial function, and neuroinflammation — and is administered subcutaneously. Herantis completed a Phase 1b trial in 2025 enrolling 24 Parkinson's disease patients, meeting all primary and secondary endpoints for safety and tolerability, with HER-096 achieving pharmacologically active concentrations in cerebrospinal fluid. Positive biomarker data were reported in January 2026 and presented at the AD/PD 2026 conference in Denmark in March 2026.

The business model is pre-revenue clinical-stage drug development. Herantis has no marketed products and currently raises capital through directed share issues (EUR 1.46 million in March 2022, EUR 5.2 million in February 2025, EUR 4.2 million in February 2026) supplemented by non-dilutive grants (a EUR 8.0 million Horizon Europe 2025 grant awarded February 2026). Support has also come from the EIC Fund, Michael J. Fox Foundation, and Parkinson's UK. As of the disclosed run-rate, the company has 11–50 employees and cash runway to Q1 2027, with management stating EUR 20–25 million of additional capital is needed to fund planned Phase 2 efficacy trials. Commercial GTM is not yet active; future commercialization would follow standard pharmaceutical wholesale and distribution pathways targeting early-stage Parkinson's disease patients.

Recent corporate actions include the May 2026 partnership with Indivi to integrate smartphone-based digital biomarker assessments into the Phase 2 trial, the June 2026 appointment of Dr Juha Savola as Chief Medical Officer (with prior senior clinical development experience at Spark Therapeutics, Teva, Roche, and Santhera), and positive FDA feedback finalized in June 2026 on the Phase 2a study design, with patient enrollment expected to begin soon. The Phase 2 proof-of-concept trial, planned for 2027, is targeted to enroll approximately 100 patients across Europe.

Short descriptiontext

Herantis Pharma is a Finnish clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to modulate multiple disease-relevant pathways in Parkinson's disease. The company is preparing for Phase 2 proof-of-concept trials targeted for 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, peptide therapeutics, neurodegenerative disease treatment, blood-brain barrier technology, Parkinson's disease therapy
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals / Neurological Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue / Clinical Stage
TypeOne Time License
Description

Herantis Pharma is a clinical-stage biotechnology company with no current revenue. The company raises capital through equity financings and non-dilutive grants to fund drug development operations.

in.investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Herantis Pharma is a clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to be a disease-modifying treatment for Parkinson's disease. The therapy modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, and is administered subcutaneously. The company has completed Phase 1b clinical trials and is preparing for Phase 2 proof-of-concept trials planned for 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1b trial met all primary and secondary endpoints for safety and tolerability
+2 more records
Product overview1 text field

Herantis Pharma is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead product is HER-096, a first-in-class blood-brain barrier penetrating peptide therapy. The company has completed Phase 1b trials demonstrating safety, tolerability, and biomarker responses, and is preparing for Phase 2 proof-of-concept trials.

Product and service1 record
1HER-096
CategoryLead therapeutic candidate / Disease-modifying peptide therapy
Description

First-in-class blood-brain barrier penetrating peptide therapy for Parkinson's disease that modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation. Designed for subcutaneous administration as a disease-modifying treatment for early-stage Parkinson's disease patients, currently advancing to Phase 2 proof-of-concept trials planned for 2027.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-19
Description

Herantis Pharma partnered with Indivi to integrate Indivi's digital biomarker platform into the upcoming Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes compared to conventional clinical assessments. Preparations for the Phase 2 study are on track.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharmaceutical company with established Parkinson's franchise (Duopa) and active CNS pipeline. Potential strategic acquirer/partner for differentiated Parkinson's assets like HER-096.

TypeEmerging player
Description

Neuroscience-focused clinical biotech acquired by AbbVie in 2024 for $8.7B. Comparable CNS clinical-stage profile and disease-modifying approach, illustrating large-pharma BD appetite for differentiated CNS pipelines.

TypeDirect peer
Description

Specialty CNS pharma commercializing Nuplazid (pimavanserin) for Parkinson's disease psychosis. Comparable CNS/Parkinson's therapeutic focus, though at a more advanced commercial stage.

TypeDirect peer
Description

Biotech developing engineered BBB-crossing therapeutics for neurodegenerative diseases including Parkinson's. Highly comparable technology approach (BBB delivery) and indication focus.

TypeBroad incumbent
Description

Large pharmaceutical company with major CNS franchise and active Parkinson's disease programs (including prasinezumab partnership with Prothena). Logical strategic acquirer/partner for HER-096.

TypeDirect peer
Description

Clinical-stage biotech developing disease-modifying therapies for Parkinson's disease (e.g., prasinezumab, partnered with Roche). Closely comparable to Herantis as a CNS-focused biotech targeting Parkinson's progression rather than symptoms.

TypeDirect peer
Description

Specialty CNS biotech focused on neurological disorders. Recently acquired by Biogen in 2024, demonstrating the BD exit path for small CNS biotechs with differentiated clinical assets.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for Parkinson's disease and other CNS disorders. Direct peer in CNS/Parkinson's clinical development with similar size and stage.

TypeDirect peer
Description

Gene therapy company developing PR001 for Parkinson's disease with GBA1 mutations. Acquired by Eli Lilly in 2021, illustrating BD exit dynamics for Parkinson's gene therapy/peptide approaches.

TypeDirect peer
Description

Clinical-stage biotech developing CNS therapies for neurodegenerative and neurodevelopmental disorders. Comparable size, clinical-stage profile, and CNS disease-modifying mechanism approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Herantis Pharma

Biopharmaceuticals / Neurological Therapeuticsherantis.com

Herantis Pharma is a Finnish clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to modulate multiple disease-relevant pathways in Parkinson's disease. The company is preparing for Phase 2 proof-of-concept trials targeted for 2027.

What Herantis Pharma does

Herantis Pharma is a Finnish clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with its primary focus on Parkinson's disease. The company is headquartered in Espoo, Finland (Bertel Jungin Aukio 1, FIN-02600), is listed on Nasdaq First North Growth Market Finland under ticker HRTIS, and operates as a public limited liability company (Herantis Pharma Oyj / Plc). The company's lead product candidate is HER-096, a first-in-class blood-brain barrier penetrating peptide therapy that modulates multiple disease-relevant pathways — proteostasis, mitochondrial function, and neuroinflammation — and is administered subcutaneously. Herantis completed a Phase 1b trial in 2025 enrolling 24 Parkinson's disease patients, meeting all primary and secondary endpoints for safety and tolerability, with HER-096 achieving pharmacologically active concentrations in cerebrospinal fluid. Positive biomarker data were reported in January 2026 and presented at the AD/PD 2026 conference in Denmark in March 2026.

The business model is pre-revenue clinical-stage drug development. Herantis has no marketed products and currently raises capital through directed share issues (EUR 1.46 million in March 2022, EUR 5.2 million in February 2025, EUR 4.2 million in February 2026) supplemented by non-dilutive grants (a EUR 8.0 million Horizon Europe 2025 grant awarded February 2026). Support has also come from the EIC Fund, Michael J. Fox Foundation, and Parkinson's UK. As of the disclosed run-rate, the company has 11–50 employees and cash runway to Q1 2027, with management stating EUR 20–25 million of additional capital is needed to fund planned Phase 2 efficacy trials. Commercial GTM is not yet active; future commercialization would follow standard pharmaceutical wholesale and distribution pathways targeting early-stage Parkinson's disease patients.

Recent corporate actions include the May 2026 partnership with Indivi to integrate smartphone-based digital biomarker assessments into the Phase 2 trial, the June 2026 appointment of Dr Juha Savola as Chief Medical Officer (with prior senior clinical development experience at Spark Therapeutics, Teva, Roche, and Santhera), and positive FDA feedback finalized in June 2026 on the Phase 2a study design, with patient enrollment expected to begin soon. The Phase 2 proof-of-concept trial, planned for 2027, is targeted to enroll approximately 100 patients across Europe.

Herantis Pharma firmographics

Firmographics
Name
Herantis Pharma
Legal name
Herantis Pharma Oyj
Website
https://herantis.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Herantis Pharma is a Finnish clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to modulate multiple disease-relevant pathways in Parkinson's disease. The company is preparing for Phase 2 proof-of-concept trials targeted for 2027.
Ownership category
akta.pro rank

Where Herantis Pharma is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Herantis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pre-Revenue / Clinical Stage: Herantis Pharma is a clinical-stage biotechnology company with no current revenue. The company raises capital through equity financings and non-dilutive grants to fund drug development operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Herantis Pharma product offering

Product offering

Core offering

Herantis Pharma is a clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to be a disease-modifying treatment for Parkinson's disease. The therapy modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, and is administered subcutaneously. The company has completed Phase 1b clinical trials and is preparing for Phase 2 proof-of-concept trials planned for 2027.

Product overview

Herantis Pharma is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead product is HER-096, a first-in-class blood-brain barrier penetrating peptide therapy. The company has completed Phase 1b trials demonstrating safety, tolerability, and biomarker responses, and is preparing for Phase 2 proof-of-concept trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • HER-096 First-in-class blood-brain barrier penetrating peptide therapy for Parkinson's disease that modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation. Designed for subcutaneous administration as a disease-modifying treatment for early-stage Parkinson's disease patients, currently advancing to Phase 2 proof-of-concept trials planned for 2027.

Quantifiable outcome

  • Phase 1b trial met all primary and secondary endpoints for safety and tolerability
  • +2 more outcomes

Companies that use Herantis Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Herantis Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Herantis Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • IndivicoreTechnology or Integration · 19 May 2026Herantis Pharma partnered with Indivi to integrate Indivi's digital biomarker platform into the upcoming Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes compared to conventional clinical assessments. Preparations for the Phase 2 study are on track.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Herantis Pharma competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Major pharmaceutical company with established Parkinson's franchise (Duopa) and active CNS pipeline. Potential strategic acquirer/partner for differentiated Parkinson's assets like HER-096.
  • Roche: Large pharmaceutical company with major CNS franchise and active Parkinson's disease programs (including prasinezumab partnership with Prothena). Logical strategic acquirer/partner for HER-096.

Emerging players

  • Cerevel Therapeutics: Neuroscience-focused clinical biotech acquired by AbbVie in 2024 for $8.7B. Comparable CNS clinical-stage profile and disease-modifying approach, illustrating large-pharma BD appetite for differentiated CNS pipelines.

Direct peers

  • Acadia Pharmaceuticals: Specialty CNS pharma commercializing Nuplazid (pimavanserin) for Parkinson's disease psychosis. Comparable CNS/Parkinson's therapeutic focus, though at a more advanced commercial stage.
  • Denali Therapeutics: Biotech developing engineered BBB-crossing therapeutics for neurodegenerative diseases including Parkinson's. Highly comparable technology approach (BBB delivery) and indication focus.
  • Prothena Corporation: Clinical-stage biotech developing disease-modifying therapies for Parkinson's disease (e.g., prasinezumab, partnered with Roche). Closely comparable to Herantis as a CNS-focused biotech targeting Parkinson's progression rather than symptoms.
  • Sage Therapeutics: Specialty CNS biotech focused on neurological disorders. Recently acquired by Biogen in 2024, demonstrating the BD exit path for small CNS biotechs with differentiated clinical assets.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for Parkinson's disease and other CNS disorders. Direct peer in CNS/Parkinson's clinical development with similar size and stage.
  • Prevail Therapeutics (Eli Lilly): Gene therapy company developing PR001 for Parkinson's disease with GBA1 mutations. Acquired by Eli Lilly in 2021, illustrating BD exit dynamics for Parkinson's gene therapy/peptide approaches.
  • Anavex Life Sciences: Clinical-stage biotech developing CNS therapies for neurodegenerative and neurodevelopmental disorders. Comparable size, clinical-stage profile, and CNS disease-modifying mechanism approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

Herantis Pharma social profiles

Digital presence

Herantis Pharma compliance and trust

Trust signal

Compliance1 record

Herantis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Herantis Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Herantis Pharma funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Herantis Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Herantis Pharma

What does Herantis Pharma do?

Herantis Pharma is a clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to be a disease-modifying treatment for Parkinson's disease. The therapy modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, and is administered subcutaneously. The company has completed Phase 1b clinical trials and is preparing for Phase 2 proof-of-concept trials planned for 2027.

Is Herantis Pharma a public or private company?

Herantis Pharma is a public company. It is classified as public and is currently operating.

When was Herantis Pharma founded?

Herantis Pharma was founded in 2008. It employs 11 to 50 people.

Where is Herantis Pharma based?

Herantis Pharma is headquartered in Espoo, Finland, in the Europe region.

How does Herantis Pharma make money?

One revenue line is on record: pre-Revenue / Clinical Stage.

Who are Herantis Pharma's main competitors?

Broad incumbents on record are AbbVie and Roche. Cerevel Therapeutics is listed as an emerging player. Direct peers are Acadia Pharmaceuticals, Denali Therapeutics, Prothena Corporation, Sage Therapeutics, Voyager Therapeutics, Prevail Therapeutics (Eli Lilly) and Anavex Life Sciences.

Does Herantis Pharma have an API?

No public API is recorded for Herantis Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialHerantis Pharma: Newly Published Clinical Evidence Validates HER-096 Phase 2 Study DesignHerantis Pharma announced its HER-096 Phase 2 study design, using smartphone-based motor assessments as the primary endpoint. The company cites evidence that these assessments are 2.5 times more sensitive to disease progression, potentially reducing participants by 80%. Clinical Trial Application submission is targeted for Q4 2026, with first dosing expected in H1 2027.Labiotech.euChanging with the times: what is the future of biomarkers in neurology?Neurology biomarkers have advanced with blood tests for Alzheimer's and seed amplification assays for Parkinson's, which detected the disease early 87% of the time. Digital biomarkers from wearables are also being explored for motor symptom tracking. Herantis Pharma plans to integrate these measures into phase 2 trials.TalouselamaPetri Suokas seuraa sijoituspäätöksissä Kyösti Kakkosta: Paljastaa nyt, minkä osakkeen uskoo olevan ”todellinen jackpot”Entrepreneur Petri Suokas, who mirrors the investment strategies of Kyösti Kakkonen, identified Latitude 66 as his preferred stock holding due to its discovery of 650,000 ounces of gold reserves. Suokas stated he will never sell this position to avoid repeating a previous negative experience with Endomines. He also highlighted his significant approximately 1.2 million euro stake in pharmaceutical development company Herantis Pharma.KauppalehtiPÖRSSI: Nousuavaus suliThe Helsinki stock exchange opened with a slight gain but quickly reversed to flat levels as early morning buying pressure dissipated. Several companies reported earnings, with Auroora Yhtiöt and Eagle Filters Group exceeding expectations, while Herantis Pharma, Nanoform, and United Bankers missed forecasts or posted losses.KauppalehtiHerantis Pharman tappio syveni – Yhtiö valmistautuu toisen vaiheen kliiniseen tutkimukseenHerantis Pharma reported a widened operating loss of 3.1 million euros for the first half of the year, exceeding analyst expectations and with zero revenue generated. The company raised 4.2 million euros through a share issue and secured an 8 million euro grant to support its development pipeline. Herantis is currently finalizing preparations for a Phase 2 clinical trial expected to begin in the first half of 2027.TalouselamaPetri Suokas seuraa sijoituspäätöksissä Kyösti Kakkosta: Paljastaa nyt, minkä osakkeen uskoo olevan ”todellinen jackpot”Entrepreneur and investor Petri Suokas, who has served on the board of Enersense, discusses his investment strategy in a Talouselämä interview, noting that he often follows the investment decisions of major investor Kyösti Kakkonen. Suokas reveals he would invest 500,000 euros in Latitude 66, a Finnish mining company that has discovered 650,000 ounces of gold reserves along with cobalt deposits, describing it as a potential "real jackpot." He also mentions being a major shareholder in Herantis Pharma with approximately 1.2 million euros invested, referencing Endomines as a past investment case he does not wish to repeat.KauppalehtiSäästöpankin rahastojen Herantis-omistus alitti viiden prosentin liputusrajanSp-rahastoyhtiö reduced its ownership in Herantis Pharma below the 5% flagging threshold, with the stake falling from 5.48% to 4.98%. The decrease resulted from share transactions conducted on Wednesday. This is a routine regulatory disclosure regarding a major shareholder crossing a mandatory reporting threshold.GlobeNewswireHerantis appoints experienced drug development expert Dr Juha Savola as Chief Medical OfficerHerantis Pharma Plc, a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease, has appointed Dr Juha Savola as its new Chief Medical Officer. Dr Savola brings over 25 years of global drug development experience in neurology, gene therapy, and rare diseases, having most recently served as Vice President of Clinical Development at Spark Therapeutics. His appointment is intended to support the advancement of HER-096, Herantis's lead therapy candidate, into Phase 2 clinical trials in 2027.NTB KommunikasjonHerantis appoints experienced drug development expert Dr Juha Savola as Chief Medical OfficerHerantis Pharma Plc, a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease, announced the appointment of Dr. Juha Savola as Chief Medical Officer. Dr. Savola brings over 25 years of global drug development experience, including senior roles at Spark Therapeutics, Teva Pharmaceuticals, Roche, and Santhera Pharmaceuticals, with expertise spanning neurology, gene therapy, and rare diseases. The appointment is intended to support the advancement of HER-096 into a Phase 2 clinical trial in 2027 for early-stage Parkinson's patients.